Project description:Covalent modification of histones is a fundamental mechanism of regulated gene expression in eukaryotes, and interpretation of histone modifications is an essential feature of epigenetic control. Bromodomains are specialized binding modules that interact with acetylated histones, linking chromatin recognition to gene transcription. Because of their ability to function in a domain-specific fashion, selective disruption of bromodomain:acetylated histone interactions with chemical probes serves as a powerful means for understanding biological processes regulated by these chromatin adaptors. Here we describe the discovery and characterization of potent and selective small molecule inhibitors for the bromodomains of CREBBP/EP300 that engage their target in cellular assays. We use these tools to demonstrate a critical role for CREBBP/EP300 bromodomains in regulatory T cell biology. Because regulatory T cell recruitment to tumors is a major mechanism of immune evasion by cancer cells, our data highlight the importance of CREBBP/EP300 bromodomain inhibition as a novel, small molecule-based approach for cancer immunotherapy.
Project description:Genome-wide gene expression changes in response to CBP inhibitor treatment in Treg cells using microarray. Expression profiling by microarray of Treg cells treated with DMSO or CBP inhibitor, and Th0 cells
Project description:Genome-wide gene expression changes in response to CBP inhibitor treatment in Treg cells using RNA sequencing (RNA-seq). Expression profiling by RNA-seq of Treg cells treated with DMSO or CBP inhibitor
Project description:Genome-wide chromatin H3K27ac, H3K18ac and H3K4me3 occupancy changes in response to CBP inhibitor treatment in Treg cells using ChIP sequencing (ChIP-seq). Expression profiling by ChIP-seq of Treg cells treated with DMSO or CBP inhibitor
Project description:Genome-wide chromatin H3K27ac, H3K18ac and H3K4me3 occupancy changes in response to CBP inhibitor treatment in Treg cells using ChIP sequencing (ChIP-seq).